ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2838

Comorbid Vasculitis Among Patients in a National Primary Immunodeficiency Database

Kevin Byram1, Leonard H. Calabrese2 and James Fernandez1, 1Cleveland Clinic Foundation, Cleveland, OH, 2Rheumatic & Immunologic Disease and Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: CNS Vasculitis, Immunodeficiency, primary immunodeficiency and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: 5T093 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os II: Novel Diagnostics & THRs (2838–2843)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Vasculitis has been reported in patients with various forms of primary immunodeficiency (PID) in case reports in the literature. The goal of this study is to evaluate the frequency of vasculitis in a large national database of patients with primary immunodeficiency.

Methods: The United States Immunodeficiency Network (USIDNET) is a large national consortium organized to collect registry data on patients with primary immune deficiencies. The USIDNET database was queried for patient records with a documented history of vasculitis. Data regarding demographics, type of vasculitis diagnosis, specific PID diagnosis, immunologic laboratory results and immunomodulatory treatment was abstracted from the records and descriptive statistics are presented. Focused analyses were also performed for patients with common variable immune deficiency (CVID) and Wiskott-Aldrich syndrome (WAS).

Results: As of March 12, 2018 data were available on 4,888 patients and 76 patients (1.6%) with vasculitis were identified. CVID (n=29, [38%]) and WAS (n=20, [26%]) were the most common PID associated with vasculitis (Table 1). Table 2 describes the results for the total PID cohort, as well as CVID and WAS sub-populations. Overall, 76% of patients were Caucasian, and 46% of patients were female. Central nervous system (CNS) vasculitis was the most common specific vasculitis syndrome identified among patients with PID in the USIDNet Registry (n=11, [14 %]). Glucocorticoids were the most frequent immunomodulatory therapy reported in all populations studied and occurred in more than half of cases (59-69%). In the CVID cohort, 29 cases of vasculitis were identified, with CNS vasculitis being the most common (n=5, [17%]). About half of cases of vasculitis were reported to be present before or at the diagnosis of the PID (n=37, [49%]) and CVID (n=14, [48%]). Henoch-Schonlein Pupura was the most common vasculitis (n=6, [30]) associated with WAS, with most cases (75%) being present before or at diagnosis of WAS.

Conclusion:    Vasculitis is an uncommon complication of PID but can be encountered in a variety of syndromes, and was most frequently associated with CVID and WAS in the USIDNet Registry. Vasculitis complicating PID can represent a challenging confounder and mimic of serious infections.  Clinicians caring for patients with PID need to be aware that vasculitis may be a rare autoimmune manifestation associated with PID especially those with CNS involvement. 


Disclosure: K. Byram, None; L. H. Calabrese, Bristol-Myers Squibb, 5, 8,Genentech, Inc., 5, 8; J. Fernandez, None.

To cite this abstract in AMA style:

Byram K, Calabrese LH, Fernandez J. Comorbid Vasculitis Among Patients in a National Primary Immunodeficiency Database [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/comorbid-vasculitis-among-patients-in-a-national-primary-immunodeficiency-database/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comorbid-vasculitis-among-patients-in-a-national-primary-immunodeficiency-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology